Organically modified hybrid aerogels
US-9527977-B2 · Dec 27, 2016 · US
US11780982B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11780982-B2 |
| Application number | US-202217728188-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 25, 2022 |
| Priority date | Jan 22, 2019 |
| Publication date | Oct 10, 2023 |
| Grant date | Oct 10, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Green, fast and easy evaporating organic solvent for use as a lubricant in the processing of polytetrafluoroethylene (PTFE) and expanded polytetrafluoroethylene (ePTFE) products and processes of using the solvents to fabricate the products are disclosed herein. The products can be used in the field of bio- and medical applications, such as for use in vascular grafts, cardiovascular and soft tissue patches, facial implants, surgical sutures, and endovascular prosthesis, and for any products known in the aerospace, electronics, fabrics, filtration, industrial and sealant arts.
Opening claim text (preview).
What is claimed is: 1. A method of preparing an extruded product, the method comprising: dissolving a target additive into an organic solvent to form a target-solvent solution; immersing a polytetrafluoroethylene (PTFE) powder in the target-solvent solution to form a blend, wherein the organic solvent is present in the blend in an amount of from about 10% by weight to about 30% by weight; preforming the blend; extruding the preformed blend to form a product; and evaporating the target-solvent solution from the extruded product. 2. The process as set forth in claim 1 , wherein the organic solvent is selected from the group consisting of a lower alkyl alcohols, acetic acid, ethyl acetate, acetonitrile, chloroform, benzene, methylbenzene, dimethylbenzene, acetone, 2-butanone, cyclopentanone, pentane, n-hexane, cyclohexane, heptane, dichloromethane, dichloroethane, trichloroethane, tetrachloromethane, tetrachloroethane, trimethylpentane, 1,4-dioxane, chloroform, ether, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF), and combinations thereof. 3. The process as set forth in claim 1 , wherein the organic solvent is further mixed with a carrier before blended with the PTFE powder. 4. The process as set forth in claim 1 , wherein blending comprising rolling the PTFE powder and organic solvent for a period of from about 30 minutes to about 120 minutes. 5. The process as set forth in claim 4 further comprising aging the blend for a period of from about 30 minutes to about 48 hours after rolling. 6. The process as set forth in claim 1 comprising preforming the blend at a pressure of from about 1 MPa to about 30 MPa. 7. The process as set forth in claim 1 , wherein evaporating of the organic solvent comprises heating the extruded product to a temperature of from 60° C. to about 200° C. for a period of from about 0.5 minutes to about 120 minutes. 8. The process as set forth in claim 1 further comprising expanding the extruded product. 9. The process as set forth in claim 1 , wherein the target additive is selected from the group consisting of a biofunctional material, a therapeutic, a natural compound, an aesthetic agent and combinations thereof. 10. The process as set forth in claim 9 , wherein the biofunctional material is a growth factor selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), granulocyte-macrophage colony-stimulating factor (GMCSF), granulocyte-colony stimulating factor (GCSF), transforming growth factor (TGF), Erythropieitn, thyroperoxidase (TPO), bone morphogenetic proteins (BMP), hepatocyte growth factor (HGF), growth differentiation factors (GDF), Neurotrophins, melanocyte-specific factor (MSF), sarcoma growth factor (SGF), and combinations thereof. 11. The process as set forth in claim 1 , wherein the target additive is present in the organic solvent in an amount of from about 0.1% by weight to about 5% by weight. 12. A method for preparing an extruded product, the method comprising: dissolving a target additive into an organic solvent to form a target-solvent solution, wherein the target additive is present in the target-solvent solution in an amount of from about 0.1% by weight to about 5% by weight; immersing a sintered extruded polytetrafluoroethylene (PTFE) product in the target-solvent solution to form a wetted PTFE product; and evaporating the target-solvent solution from the extruded product. 13. The process as set forth in claim 12 , wherein evaporating of the target-solvent solution comprises heating the extruded product to a temperature of from 60° C. to about 200° C. for a period of from about 0.5 minutes to about 120 minutes. 14. The process as set forth in claim 12 , wherein the target additive is selected from the group consisting of a biofunctional material, a therapeutic, a natural compound, an aesthetic agent and combinations thereof. 15. The process as set forth in claim 14 , wherein the biofunctional material is a growth factor selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), granulocyte-macrophage colony-stimulating factor (GMCSF), granulocyte-colony stimulating factor (GCSF), transforming growth factor (TGF), Erythropieitn, thyroperoxidase (TPO), bone morphogenetic proteins (BMP), hepatocyte growth factor (HGF), growth differentiation factors (GDF), Neurotrophins, melanocyte-specific factor (MSF), sarcoma growth factor (SGF), and combinations thereof.
the liquid phase being a solvent for the monomers but not for the resulting macromolecular composition, i.e. macroporous or macroreticular polymers · CPC title
obtained by reactions only involving carbon-to-carbon unsaturated bonds · CPC title
Porous materials, {e.g. foams or sponges} · CPC title
Hydrocarbons · CPC title
Extrusion of the foamable blend · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.